Landmark trial
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
Gillison ML, Trotti AM, Harris J, et al.
DoseLab summary
Phase 3 NRG Oncology trial comparing cetuximab with cisplatin, both given with accelerated IMRT (70 Gy in 35 fractions over 6 weeks), in HPV-positive oropharyngeal cancer. Citation checked against Crossref; content not yet reviewed by DoseLab.
Why this is useful
Showed cetuximab was inferior to cisplatin with accelerated IMRT for HPV-positive oropharynx cancer, keeping cisplatin as the standard concurrent drug.
Reference details
- Title
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
- Authors / organization
- Gillison ML, Trotti AM, Harris J, et al.
- Publication / protocol
- Lancet. 2019;393(10166):40–50
- Version
- Pending verification
- Year
- 2019
- DOI
- 10.1016/S0140-6736(18)32779-X
- Disease sites
- Head & Neck
- Topics
- Head & Neck, Oropharynx, HPV, Chemoradiation, Landmark trial, NRG, RTOG
- Fractionation context
- 70 Gy / 35 fx, 6 fractions per week
- Last reviewed by DoseLab
- Pending verification